About Adgero Biopharma
Adgero Biopharma is a company based in Princeton (United States) founded in 2012 was acquired by DelMar Pharmaceuticals in June 2020. Adgero Biopharma has raised $5.52 million across 5 funding rounds from investors including HHS, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co and DelMar Pharmaceuticals. Adgero Biopharma operates in a competitive market with competitors including PhotoPharmics, CranioVation, Lumeda, Illumi Medical and SpectraCure, among others.
- Headquarter Princeton, United States
- SectorsHealthcareTechnology
- Email••••••••
- Website adgerobiopharm.com
- Social LinkedIn X Facebook
- Acquired by DelMar Pharmaceuticals (Jun 2020)
- Total Equity Funding$5.52M (USD)
in 5 rounds
- Latest Funding Round$225K (USD), Grant
Jul 2020
- InvestorsHHS
& 2 more
- Acquired byDelMar Pharmaceuticals
(Jun 2020)
Funding Insights of Adgero Biopharma
Adgero Biopharma has successfully raised a total of $5.52M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $225 thousand completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.52M
- Total Rounds 5
- Last Round Grant — $225,000
- First Round $39,750
(Nov 2015)
- Investors Count 2
All 5 funding rounds of Adgero Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $225,000 | Grant | – | – | |
| Feb 2017 | $2M | Series A | – | – | |
| Sep 2016 | $459,000 | Series A | – | – | – |
| Apr 2016 | $3.02M | Series A | – | – | – |
| Nov 2015 | $39,750 | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in Adgero Biopharma
Adgero Biopharma has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co and DelMar Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Photosensitizers and nano-formulations for cancer treatments are developed. | 1996 | fd-zj.com | Pudong, China | |
Drug candidates targeting orphan cancer indications are developed. | 2010 | delmarpharma.com | Vancouver, Canada |
Investor details for Adgero Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adgero Biopharma
1 people are tracked at Adgero Biopharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Robert E. Hoffman | President, CEO, CFO & Chairman | Leadership |
Complete people profiles for Adgero Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Adgero Biopharma
4 dated milestones of Adgero Biopharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Adgero Biopharma is founded.
- Funding First funding round of $40K.
- Exit Acquired by DelMar Pharmaceuticals.
- Funding Latest funding round, Grant, of $225K.
Competitors of Adgero Biopharma
Adgero Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PhotoPharmics, CranioVation, Lumeda, Illumi Medical and SpectraCure, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| photopharmics.com | 2011 | American Fork, United States | $43.44M | – | Non-invasive phototherapy for Parkinson's disease is developed. | |
| craniovation.com | 2017 | Rochester, United States | $7.61M | – | Minimally invasive devices for brain tumor treatment are provided. | |
| lumedainc.com | 2020 | Rocky Hill, United States | $5.34M | 10 | Photodynamic therapy device for lung cancer treatment is developed. | |
| illumimedical.com | 2023 | Nagoya, Japan | $2.26M | – | Photodynamic therapy devices for cancer treatment are developed. | |
| spectracure.com | 2003 | Lund, Sweden | – | – | Developer of Interstitial photo dynamic therapy for solid tumours | |
| impactbiotech.com | 2022 | Ness Ziona, Israel | – | – | Developer of a drug delivery platform for the treatment of solid tumors | |
| photolitec.org | 2010 | Buffalo, United States | $5M | – | Supplies photosensitizing compounds for tumor imaging and photodynamic cancer therapy. | |
| illumacell.com | 2008 | Waterloo, Canada | – | – | Provider of medical light technology for photodynamic therapy cancer treatment |
Detailed competitors of Adgero Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adgero Biopharma
Complete news archive for Adgero Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Adgero Biopharma
10 companies that operate in the same segment as Adgero Biopharma (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adgero Biopharma
Adgero Biopharma was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Adgero Biopharma is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Adgero Biopharma is a funded company, having raised a total of $5.52M across 5 funding rounds to date. The company's 1st funding round was a Seed of $39.75K, raised on Nov 2015.
Adgero Biopharma was founded in 2012 in Princeton, United States, within the biopharmaceutical sector. Focus is placed on advancing photodynamic therapy for patients with cutaneous metastatic breast cancer. The treatment system incorporates a laser light source, a light delivery device, and the drug Rostaporfin. Operations center on developing and refining this therapy to address unmet needs in oncology care.
Adgero Biopharma's top competitors include PhotoPharmics, ImPact Biotech and CranioVation.
Adgero Biopharma has 3 investors. Key investors include HHS, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co, and DelMar Pharmaceuticals.
Yes. Adgero Biopharma was acquired by DelMar Pharmaceuticals in June 2020.